Long Term Treatment With Galantamine In Dementia
Abstract
The purpose of this study is to evaluate the long-term efficacy and safety of galantamine in patients with Alzheimer's disease.
Conditions: Alzheimer Disease, Dementia, Mental Disorders, Brain Diseases.
Primary outcome: Time to worsening of symptoms, defined as the time from the beginning of the double-blind portion of the study to the time of an increase in ADAS-cog score of > or = to 4 points.
Enrollment: 254 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 254 participants or records.
Read the paper
Related studies
- Diarylethenes for Memories and Switches
- Long-Term Potentiation and Memory
- Social Memory Studies: From “Collective Memory” to the Historical Sociology of Mnemonic Practices
- The Cognitive Neuroscience of Working Memory
- Memory aging and brain maintenance
- Effector and Memory CTL Differentiation
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.